Ottawa Hospital Research Institute

Summary

Ottawa Hospital Research Institute is a medical facility located in OTTAWA, Ontario. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Prostate Cancer, Stroke and other specialties. Ottawa Hospital Research Institute is involved with conducting 219 clinical trials across 289 conditions. There are 26 research doctors associated with this hospital, such as John Hilton, MD, Dar Dowlatshahi, MD, Scott C. Morgan, and Scott A Laurie.

Top PIs

Clinical Trials running at Ottawa Hospital Research Institute

Stroke

Melanoma

Prostate Cancer

Multiple Myeloma

Age-Related Macular Degeneration

Head and Neck Cancers

Cancer

Lymphoma

Breast Cancer

Colorectal Cancer

Care Bundle

for Stroke

Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.

Recruiting

2 awards

Phase 4

1 criteria

NoNO-42

for Stroke

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial. A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.

Recruiting

1 award

Phase 2

3 criteria

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.

Recruiting

1 award

Phase 3

2 criteria